Why a manufacturing failure makes a drug adulterated

The rulebook, and the sentence sitting in front of it

Articles across this site quote the same opening line from the manufacturing regulation for finished pharmaceuticals. It contains the minimum current good manufacturing practice for preparing drug products for administration to humans or animals.

That sentence says what the rulebook is about. It does not say what happens when a rule inside it is broken.

The answer sits in a much shorter part immediately before it, which holds exactly three sections. Almost nobody cites it, and the whole system hangs off one of its paragraphs.

One family of rules, five parts

The first of those three sections states what the family covers. The regulations in that part and in four others "contain the minimum current good manufacturing practice" for a drug. The phrase reaches "methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug".

Then it names the purpose, and the wording is worth slowing down for. Those rules exist "to assure that such drug meets the requirements of the act as to safety". The sentence goes on: the drug also "has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess".

The last clause is not the regulator's own phrase. It is lifted from the statute, which uses the same words in the adulteration section.

So the standard a batch is held to is partly the one the product claims for itself. This site follows that idea through the compendial and pharmaceutical-grade claims a seller makes, in a separate article.

The sentence

The next paragraph is the hinge of the whole arrangement, and it is one sentence long.

It begins: "The failure to comply with any regulation set forth in this part and in parts 211, 213, 225, and 226 of this chapter". The failure has to occur "in the manufacture, processing, packing, or holding of a drug", and it then "shall render such drug to be adulterated under section 501(a)(2)(B) of the act". The clause closes by reaching a person: "such drug, as well as the person who is responsible for the failure to comply, shall be subject to regulatory action".

Two consequences arrive together and they are not the same consequence. The drug is adulterated. And a person is separately answerable.

Note the word "any". The sentence carries no severity test of its own. A record that was not signed and a filter that was not tested reach the conclusion by the same route.

Where that pointer goes

The sentence names section 501(a)(2)(B) of the act, which is a citation to the statute rather than to another regulation.

Section 501 of the act is the adulteration section, published in the United States Code as section 351 of title 21. The Code prints the origin in its source credit, which begins with the 1938 enactment and names section 501.

Reading the statutory paragraph makes the shape of the system visible. The ground is "the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding". A drug is adulterated where those "do not conform to or are not operated or administered in conformity with current good manufacturing practice".

The subject of that sentence is the methods, the facilities and the controls. It is not the vial.

The statute says what the term includes

The adulteration section closes with a paragraph that most citations skip, because it sits after the last lettered subsection instead of inside one.

It opens "For purposes of paragraph (a)(2)(B)" and then says what the term includes. Current good manufacturing practice "includes the implementation of oversight and controls over the manufacture of drugs to ensure quality". That expressly covers "managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products".

Raw materials are named first. For a compounded peptide that is the starting powder, and this site follows what happens to it before it becomes a medicine in its own article.

The Code records the paragraph as concluding provisions inserted by a 2012 act. It is not a subsection, and citing it as one would put a real quotation at an address that does not exist.

Why a clean test result does not answer the question

If the ground were the contents, a passing assay would settle it. The ground is the process, so it does not.

A result describes one sample at one moment. The regulation asks whether the methods, facilities and controls were operated in conformity with the practice, across a whole batch and a whole run.

That is the same reason a certificate of analysis is a summary of work rather than proof of it, which this site covers where testing belongs.

It also explains something readers find odd in agency correspondence. A letter can describe a manufacturing failure without ever saying that a product was contaminated, because the section it rests on does not ask that question.

Who is actually held to it

The scope has to be read twice, because the sentence above is easy to over-apply.

The regulation says what the rules are and what failing one means. It does not decide who is subject to them. The next section of the same part is about applicability, and the compounding sections of the statute settle the rest.

The statutory exemption for a compounded prescription opens by naming three sections that "shall not apply to a drug product" meeting its conditions, and the manufacturing-practice provision is the first of the three.

The registration route for an outsourcing facility opens the same way and names three sections as well, and the manufacturing-practice provision is not among them.

So one category of compounder is released from the requirement and the other is not, and the difference is written in the compounding sections rather than in the manufacturing rules. This site covers both routes in their own articles.

Nothing here says which category any particular pharmacy belongs to. That is a fact about a named facility, and it is not visible from a product page.

What to hold on to

The long rulebook does not contain its own consequence. A short part in front of it supplies one, in a single sentence.

That sentence attaches to any failure, names the statute it runs through, and reaches both the drug and the person responsible.

The statutory ground it points at is written about methods, facilities and controls, which is why a good result on a finished vial does not dispose of it.

And which compounders carry that requirement is decided somewhere else entirely, in the two sections that describe compounding itself.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations section 210.1, Status of current good manufacturing practice regulations, whose paragraph (b) provides that failure to comply with any regulation in that part and in parts 211, 213, 225 and 226 renders the drug adulterated under section 501(a)(2)(B) of the act and subjects the drug and the responsible person to regulatory action — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
2. Title 21 United States Code section 351, Adulterated drugs and devices, paragraph (a)(2)(B) on methods, facilities and controls, and the concluding provisions stating what the term current good manufacturing practice includes — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
3. Title 21 Code of Federal Regulations section 211.1, Scope, stating that the part contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
4. Title 21 United States Code section 353a, Pharmacy compounding, whose opening subsection names sections 351(a)(2)(B), 352(f)(1) and 355 as the provisions that shall not apply to a qualifying compounded drug product — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
5. Title 21 United States Code section 353b, Outsourcing facilities, whose opening subsection names sections 352(f)(1), 355 and 360eee-1, and does not name section 351(a)(2)(B) — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026